A Multi-center, Randomized, Open-label Clinical Trial Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in High Tumor Burden mHSPC
Latest Information Update: 24 Jul 2023
At a glance
- Drugs Rezvilutamide (Primary) ; Docetaxel
- Indications Adenocarcinoma; Bone metastases; Cancer metastases; Prostate cancer
- Focus Therapeutic Use
Most Recent Events
- 24 Jul 2023 New trial record